These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 31371588)

  • 21. BORIS in human cancers -- a review.
    Martin-Kleiner I
    Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypomethylation of BORIS is a promising prognostic biomarker in hepatocellular carcinoma.
    He J; Huang Y; Liu Z; Zhao R; Liu Q; Wei L; Yu X; Li B; Qin Y
    Gene; 2017 Sep; 629():29-34. PubMed ID: 28764977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Preparation of the monoclonal antibodies against human BORIS and the expression pattern of BORIS in normal and diseased human mammary tissues].
    Zhou XC; Song CJ; Wang X; Tian Y; Jin BQ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Apr; 23(4):353-5. PubMed ID: 17428394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EUROPE. 'Brexit' casts pall on future of U.K. science.
    Clery D
    Science; 2016 Jul; 353(6294):12-3. PubMed ID: 27365429
    [No Abstract]   [Full Text] [Related]  

  • 25. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.
    Kholmanskikh O; Loriot A; Brasseur F; De Plaen E; De Smet C
    Int J Cancer; 2008 Feb; 122(4):777-84. PubMed ID: 17957795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of promoter methylation and polymorphic minisatellites of BORIS and lack of association with gastric cancer.
    Yoon SL; Roh YG; Lee SH; Kim SH; Kim MC; Kim SJ; Leem SH
    DNA Cell Biol; 2011 Sep; 30(9):691-8. PubMed ID: 21495859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.
    Tiffen JC; Bailey CG; Marshall AD; Metierre C; Feng Y; Wang Q; Watson SL; Holst J; Rasko JE
    Int J Cancer; 2013 Oct; 133(7):1603-13. PubMed ID: 23553099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
    Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
    Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein.
    Schwarzenbach H; Eichelser C; Steinbach B; Tadewaldt J; Pantel K; Lobanenkov V; Loukinov D
    BMC Cancer; 2014 Nov; 14():796. PubMed ID: 25363021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
    Alberti L; Losi L; Leyvraz S; Benhattar J
    PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
    Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
    Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased expression of brother of the regulator of imprinted sites in peripheral blood neutrophils is associated with both benign and malignant breast lesions.
    El-Sharkawy NM; Radwan WM; Essa ES; Kandeel EZ; Abd El-Fattah EK; Kandil SH; Kamel AM
    Cytometry B Clin Cytom; 2017 Sep; 92(5):355-360. PubMed ID: 27219508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility.
    Yoon SL; Roh YG; Chu IS; Heo J; Kim SI; Chang H; Kang TH; Chung JW; Koh SS; Larionov V; Leem SH
    Exp Mol Med; 2016 Jul; 48(7):e246. PubMed ID: 27416782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
    Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
    Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of a testis-specific form of Gal3st1 (CST), a gene essential for spermatogenesis, is regulated by the CTCF paralogous gene BORIS.
    Suzuki T; Kosaka-Suzuki N; Pack S; Shin DM; Yoon J; Abdullaev Z; Pugacheva E; Morse HC; Loukinov D; Lobanenkov V
    Mol Cell Biol; 2010 May; 30(10):2473-84. PubMed ID: 20231363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer.
    Zhang Y; Fang M; Song Y; Ren J; Fang J; Wang X
    Sci Rep; 2017 Jan; 7():40786. PubMed ID: 28098226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway.
    Garikapati KR; Patel N; Makani VKK; Cilamkoti P; Bhadra U; Bhadra MP
    Biochem Biophys Res Commun; 2017 Feb; 484(1):93-99. PubMed ID: 28104398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Testis-specific transcriptional regulators selectively occupy BORIS-bound CTCF target regions in mouse male germ cells.
    Rivero-Hinojosa S; Kang S; Lobanenkov VV; Zentner GE
    Sci Rep; 2017 Feb; 7():41279. PubMed ID: 28145452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
    Horibe R; Hirohashi Y; Asano T; Mariya T; Suzuki T; Takaya A; Saijo H; Shionoya Y; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Watanabe K; Atsuyama E; Toji S; Hirano H; Hasegawa T; Takahashi H; Sato N; Torigoe T
    PLoS One; 2017; 12(3):e0171460. PubMed ID: 28248963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
    Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
    Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.